Conference abstractPublished 2018
Dopaminergic agonist pramipexole enhances regulatory T cell response after one-year treatment in Parkinson disease patients
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: The loss of dopaminergic neurons in Parkinson disease (PD) is associated to a neuro inflammatory process leading to neurodegeneration. PD treatment compensates the lack of dopamine resulting from the death of dopaminergic neurons. The dopaminergic agonist pramipexole has shown a neuroprotective effect by mechanisms yet unknown. On the other hand, several studies have shown that both inflammatory and anti-inflammatory immune cells can be stimulated by dopamine and dopaminergic agonists. In fact, regulatory T cells (Tregs), critical in restraining the inflammatory response, express dopamine receptors. This work is aimed to determine the effect of pramipexole on Treg-mediated immunoregulatory responses. Methodology & Theoretical Orientation: 30 untreated PD patients (scoring 1-2 in the Hoen & Yar scale, H&Y) and 22 healthy controls were included. Peripheral blood samples were taken at inclusion and one year after treatment. The levels of classical CD4+CD25+FOXP3+CD127low/-, resting CD4+CD45RO-FOXP3low, non-Tregs CD4+CD45RO+FOXP3med, activated CD4+CD45RO+FOXP3hi, Tr1 CD4+CD25hiIL-10+ and Th3 CD4+CD25hiTGF-beta+Treg cells were determined. Patient status was assessed by the UPDRS and H&Y scales. Treatment consisted of the dopamine agonist pramipexole alone or combined with levodopa. Findings: At inclusion, PD patients showed significantly lower levels of classical, activated and Tr1 Tregs than controls. After treatment, no differences were found in these populations between patients and controls. As expected, the patients showed a significant increase in the levels of classical, activated, and Tr1 cells after treatment. A decrease in the scores of the UPDRS and H&Y scales was also observed. Conclusion & Significance: PD is characterized by decreased Treg levels. Our results at inclusion show the specific subpopulations diminished (classical, activated, and Tr1). Treatment promoted an increase in Treg levels, suggesting a recovery in the regulatory immune response that could contribute to suppress neurodegeneration-related inflammatory processes. Interestingly, Treg recovery coincided with decreased scores in the UPDRS and H&Y scales.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology & Neurophysiology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Laura Adalid-Peralta”
- BylineArticles whose byline prints “Diana Alvarez-Luquin”
- BylineArticles whose byline prints “Asiel Arce-Sillas”
- BylineArticles whose byline prints “Jaquelin Leyva-Hernandez”
- BylineArticles whose byline prints “Esteban Montes-Moratilla”
- BylineArticles whose byline prints “Catherin Boll”
- BylineArticles whose byline prints “UlisesRodriguez-Ortiz”
- BylineArticles whose byline prints “Gladis Fragoso”
